Laboratorios Farmaceuticos ROVI (ROVI)

Real-time derived
Currency in EUR
51.950
-0.300(-0.57%)
Closed
ROVI Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
51.90052.600
52 wk Range
51.35094.800
Key Statistics
Edit
Prev. Close
51.95
Open
52.2
Day's Range
51.9-52.6
52 wk Range
51.35-94.8
Volume
85.69K
Average Vol. (3m)
87.95K
1-Year Change
-33.48%
Book Value / Share
11.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ROVI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
77.138
Upside
+48.48%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Laboratorios Farmaceuticos ROVI Company Profile

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Employees
2197
Market
Spain

Laboratorios Farmaceuticos ROVI Earnings Call Summary for Q4/2024

  • Rovi's Q4 2024 operating revenue fell 7.9% to €763.7M, with EBITDA down 15% to €207.4M and net profit down 20% to €136.9M
  • Specialty pharmaceutical sales grew 2%, driven by OKEDI's expansion; gross margin improved 3.7 percentage points to 62.7%
  • Company invested in CapEx, acquired stake in SELSIA Technologies, and plans further international expansion and product launches
  • Executives expect mid-single-digit revenue decline in 2025, viewing it as a transition year for future growth
  • Stock trades near 52-week low; InvestingPro suggests undervaluation with P/E of 17.8x and 17-year dividend history
Last Updated: 02/25/2025, 05:15 AM
Read Full Transcript

Compare ROVI to Peers and Sector

Metrics to compare
ROVI
Peers
Sector
Relationship
P/E Ratio
19.4x18.0x−0.5x
PEG Ratio
−1.170.230.00
Price / Book
4.6x2.0x2.6x
Price / LTM Sales
3.5x2.2x3.0x
Upside (Analyst Target)
47.8%25.4%56.3%
Fair Value Upside
Unlock21.7%10.0%Unlock

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 77.138
(+48.48% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.67
Dividend Yield
1.72%
Industry Median 0.75%
Annualized Payout
0.894
Paid annually
5-Years Growth
+39.80%
Growth Streak

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
-- / --
Revenue / Forecast
199.10M / 191.06M
EPS Revisions
Last 90 days

People Also Watch

1.731
UNI
+1.76%
25.880
IDR
+3.52%
17.42
PUIGb
-0.23%
5.355
COL
+1.81%
3.232
SCYR
+1.38%

FAQ

What Is the Laborat.Rovi (ROVI) Stock Price Today?

The Laborat.Rovi stock price today is 51.95

What Stock Exchange Does Laborat.Rovi Trade On?

Laborat.Rovi is listed and trades on the Madrid stock exchange.

What Is the Stock Symbol for Laborat.Rovi?

The stock symbol for Laborat.Rovi is "ROVI."

Does Laborat.Rovi Pay Dividends? What’s The Current Dividend Yield?

The Laboratorios Farmaceuticos ROVI dividend yield is 1.72%.

What Is the Laborat.Rovi Market Cap?

As of today, Laborat.Rovi market cap is 2.66B.

What is Laborat.Rovi Earnings Per Share?

The Laborat.Rovi EPS is 2.67.

What Is the Next Laborat.Rovi Earnings Date?

Laborat.Rovi will release its next earnings report on May 07, 2025.

From a Technical Analysis Perspective, Is ROVI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.